Ernexa Therapeutics Inc. (ERNA)
NASDAQ: ERNA · Real-Time Price · USD
0.191
-0.009 (-4.60%)
At close: Apr 28, 2026, 4:00 PM EDT
0.195
+0.004 (2.20%)
After-hours: Apr 28, 2026, 5:11 PM EDT
Ernexa Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | - | 0.58 | 0.07 | - | - | |
| Revenue Growth (YoY) | - | 755.88% | - | - | - | |
| Cost of Revenue | - | 0.1 | 0.24 | - | - | |
| Gross Profit | - | 0.49 | -0.17 | - | - | |
| Selling, General & Admin | 5.16 | 13.13 | 14.77 | 16.84 | 14.72 | |
| Research & Development | 4.16 | 4.6 | 5.73 | 10.39 | 12.71 | |
| Operating Expenses | 9.32 | 17.74 | 20.51 | 27.23 | 27.43 | |
| Operating Income | -9.32 | -17.25 | -20.68 | -27.23 | -27.43 | |
| Interest Expense | -0.03 | -6.75 | -0.61 | -0.03 | -0.07 | |
| Interest & Investment Income | 0.08 | 0.25 | 0.14 | - | - | |
| Other Non Operating Income (Expenses) | -5.63 | -0.98 | -0.12 | 9.89 | -0 | |
| EBT Excluding Unusual Items | -14.89 | -24.73 | -21.27 | -17.36 | -27.5 | |
| Merger & Restructuring Charges | - | - | - | - | -5.77 | |
| Gain (Loss) on Sale of Investments | - | - | -0.06 | -0.94 | - | |
| Gain (Loss) on Sale of Assets | - | - | - | - | -9.65 | |
| Other Unusual Items | 0.77 | -19.78 | 0.12 | -0.24 | 0.97 | |
| Pretax Income | -14.13 | -44.51 | -21.67 | -24.53 | -122.48 | |
| Income Tax Expense | -0.05 | 0.03 | -0 | 0.05 | 0.06 | |
| Net Income | -14.08 | -44.54 | -21.67 | -24.58 | -122.55 | |
| Preferred Dividends & Other Adjustments | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | |
| Net Income to Common | -14.1 | -44.56 | -21.68 | -24.6 | -122.56 | |
| Shares Outstanding (Basic) | 6 | 1 | 0 | 0 | 0 | |
| Shares Outstanding (Diluted) | 6 | 1 | 0 | 0 | 0 | |
| Shares Change (YoY) | 593.08% | 156.87% | 74.17% | 40.92% | 146.19% | |
| EPS (Basic) | -2.24 | -48.96 | -61.21 | -120.92 | -849.15 | |
| EPS (Diluted) | -2.24 | -48.96 | -61.21 | -120.92 | -849.15 | |
| Free Cash Flow | -7.05 | -16.21 | -20.43 | -21.27 | -23.64 | |
| Free Cash Flow Per Share | -1.12 | -17.81 | -57.66 | -104.59 | -163.80 | |
| Gross Margin | - | 83.50% | -247.06% | - | - | |
| Operating Margin | - | -2963.92% | -30404.41% | - | - | |
| Profit Margin | - | -7655.50% | -31888.23% | - | - | |
| Free Cash Flow Margin | - | -2784.36% | -30039.71% | - | - | |
| EBITDA | -9.25 | -17.11 | -20.59 | -27.07 | -27.31 | |
| D&A For EBITDA | 0.07 | 0.14 | 0.08 | 0.16 | 0.12 | |
| EBIT | -9.32 | -17.25 | -20.68 | -27.23 | -27.43 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.